HC Wainwright Issues Positive Outlook for BNGO Earnings

Bionano Genomics, Inc. (NASDAQ:BNGO) – Investment analysts at HC Wainwright upped their Q3 2026 earnings estimates for Bionano Genomics in a research note issued to investors on Monday, April 13th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.56) per share for the quarter, up from their previous forecast of ($0.57). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. HC Wainwright also issued estimates for Bionano Genomics’ Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($2.49) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bionano Genomics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bionano Genomics has an average rating of “Hold” and an average price target of $6.00.

Bionano Genomics Trading Up 5.8%

BNGO opened at $1.28 on Wednesday. The company has a quick ratio of 1.74, a current ratio of 1.98 and a debt-to-equity ratio of 0.08. Bionano Genomics has a 52 week low of $1.06 and a 52 week high of $5.50. The business’s 50 day moving average is $1.15 and its two-hundred day moving average is $1.49. The firm has a market cap of $14.20 million, a price-to-earnings ratio of -0.27 and a beta of 1.60.

Bionano Genomics (NASDAQ:BNGO) last posted its earnings results on Monday, March 23rd. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.78. The business had revenue of ($20,528.49) million for the quarter, compared to analysts’ expectations of $7.88 million. Bionano Genomics had a negative return on equity of 56.22% and a negative net margin of 92.59%.

Institutional Trading of Bionano Genomics

Several hedge funds have recently made changes to their positions in BNGO. Geode Capital Management LLC increased its stake in shares of Bionano Genomics by 148.8% during the fourth quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock worth $102,000 after acquiring an additional 39,928 shares during the period. Renaissance Technologies LLC acquired a new stake in Bionano Genomics in the fourth quarter valued at about $57,000. DRW Securities LLC purchased a new stake in Bionano Genomics in the 4th quarter valued at approximately $258,000. Jane Street Group LLC purchased a new stake in Bionano Genomics in the 4th quarter valued at approximately $34,000. Finally, Carret Asset Management LLC increased its position in Bionano Genomics by 76.4% during the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock worth $67,000 after purchasing an additional 19,100 shares during the period. Institutional investors and hedge funds own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.